Patents Assigned to 20/20/GeneSystems, Inc.
  • Publication number: 20240112811
    Abstract: Embodiments of the present invention relate generally to non-invasive methods and tests that measure biomarkers (e.g., tumor antigens) and collect clinical parameters from patients, and computer-implemented machine learning methods, apparatuses, systems, and computer-readable media for assessing a likelihood that a patient has a disease, relative to a patient population or a cohort population. In one embodiment, a classifier is generated using a machine learning system based on training data from retrospective data and subset of inputs (e.g. at least two biomarkers and at least one clinical parameter), wherein each input has an associated weight and the classifier meets a predetermined Receiver Operator Characteristic (ROC) statistic, specifying a sensitivity and a specificity, for correct classification of patients.
    Type: Application
    Filed: April 4, 2023
    Publication date: April 4, 2024
    Applicant: 20/20 GeneSystems Inc.
    Inventors: Jonathan Cohen, Jodd Readick, Victoria Doseeva, Peichang SHI, Jose Miguel Flores-Fernandez
  • Patent number: 11733249
    Abstract: A method of data interpretation from a multiplex cancer assay is described. The aggregate normalized score from the assay is transformed to a quantitative risk score quantifying a human subject's increased risk for the presence of cancer as compared to the known prevalence of the cancer in the population before testing the subject.
    Type: Grant
    Filed: November 12, 2018
    Date of Patent: August 22, 2023
    Assignee: 20/20 GeneSystems Inc.
    Inventors: Michael Lebowitz, Ronald Shore
  • Publication number: 20190131016
    Abstract: Embodiments of the present invention relate generally to non-invasive methods and diagnostic tests that measure biomarkers (e.g., tumor antigens), clinical parameters and computer-implemented machine learning methods, apparatuses, systems, and computer-readable media for assessing a likelihood that a patient with radiographic apparent pulmonary nodules are malignant as compared to benign, relative to a patient population or a cohort population. By utilizing algorithms generated from the biomarker levels (e.g., tumor antigens) from large volumes of longitudinal or prospectively collected blood samples (e.g., real world data from one or more regions where blood based tumor biomarker cancer screening is commonplace) together with one or more clinical parameters (e.g. age, smoking history, disease signs or symptoms) a risk level of that patient having malignant pulmonary nodules is provided.
    Type: Application
    Filed: April 1, 2017
    Publication date: May 2, 2019
    Applicant: 20/20 GeneSystems Inc.
    Inventors: Jonathan Cohen, Victoria Doseeva, Peichang Shi
  • Patent number: 10156575
    Abstract: A method of data interpretation from a multiplex cancer assay is described. The aggregate normalized score from the assay is transformed to a quantitative risk score quantifying a human subject's increased risk for the presence of cancer as compared to the known prevalence of the cancer in the population before testing the subject.
    Type: Grant
    Filed: April 10, 2017
    Date of Patent: December 18, 2018
    Assignee: 20/20 GeneSystems, Inc.
    Inventors: Michael Lebowitz, Ronald Shore
  • Publication number: 20180045730
    Abstract: A method for identifying cancer patients that are likely to be responders or non-responders to a signal transduction pathway inhibitor is described.
    Type: Application
    Filed: July 21, 2017
    Publication date: February 15, 2018
    Applicant: 20/20 GeneSystems, Inc.
    Inventors: Jonathan Cohen, Alexandrine Josephe Derrien-Colemyn, John Gillespie, Soon Sik Park
  • Patent number: 9753043
    Abstract: A method of data interpretation from a multiplex cancer assay is described. The aggregate normalized score from the assay is transformed to a quantitative risk score quantifying a human subject's increased risk for the presence of cancer as compared to the known prevalence of the cancer in the population before testing the subject.
    Type: Grant
    Filed: December 18, 2012
    Date of Patent: September 5, 2017
    Assignee: 20/20 GeneSystems, Inc.
    Inventors: Michael Lebowitz, Ronald Shore
  • Patent number: 8779312
    Abstract: The present disclosure provides methods, devices and kits that permit large numbers of target biomolecules to be detected simultaneously in samples originating from a multi-sample holder, such as a multi-well plate. One specific example method is a method of making multiple substantial replicas of a biomolecular content of a multi-well sample holder. Devices and kits for carrying out the described methods are also provided.
    Type: Grant
    Filed: November 25, 2009
    Date of Patent: July 15, 2014
    Assignees: United States of America/NIH, 20/20 Genesystems, Inc.
    Inventors: Vladimir Knezevic, Dan-Paul Hartmann, Michael R. Emmert-Buck
  • Publication number: 20130196868
    Abstract: A method of data interpretation from a multiplex cancer assay is described. The aggregate normalized score from the assay is transformed to a quantitative risk score quantifying a human subject's increased risk for the presence of cancer as compared to the known prevalence of the cancer in the population before testing the subject.
    Type: Application
    Filed: December 18, 2012
    Publication date: August 1, 2013
    Applicant: 20/20 GENESYSTEMS, INC.
    Inventor: 20/20 GENESYSTEMS, INC.
  • Patent number: 7838222
    Abstract: The present disclosure provides methods, devices and kits that permit large numbers of target biomolecules to be detected simultaneously in samples originating from a multi-sample holder, such as a multi-well plate. One specific example method is a method of making multiple substantial replicas of a biomolecular content of a multi-well sample holder. Devices and kits for carrying out the described methods are also provided.
    Type: Grant
    Filed: March 22, 2006
    Date of Patent: November 23, 2010
    Assignees: United States of America/ NIH, 20/20 Genesystems, Inc.
    Inventors: Vladimir Knezevic, Dan-Paul Hartmann, Michael R. Emmert-Buck
  • Patent number: 6969615
    Abstract: The present disclosure is directed to devices, arrays, kits and methods for detecting biomolecules in a tissue section (such as a fresh or archival sample, tissue microarray, or cells harvested by an LCM procedure) or other substantially two-dimensional sample (such as an electrophoretic gel or cDNA microarray) by creating “carbon copies” of the biomolecules eluted from the sample and visualizing the biomolecules on the copies using one or more detector molecules (e.g., antibodies or DNA probes) having specific affinity for the biomolecules of interest. Specific methods are provided for identifying the pattern of biomolecules (e.g., proteins and nucleic acids) in the samples. Other specific methods are provided for the identification and analysis of proteins and other biological molecules produced by cells and/or tissue, especially human cells and/or tissue.
    Type: Grant
    Filed: November 20, 2001
    Date of Patent: November 29, 2005
    Assignees: 20/20 GeneSystems, Inc., The United States of America as represented by the Department of Health and Human Services
    Inventors: Vladimir Knezevic, Michael R. Emmert-Buck, Galina Baibakova, Dan-Paul Hartmann, Stephen M. Hewitt, Capre Denise Mitchell, Kevin Gardner
  • Patent number: 6958242
    Abstract: Provided herein are methods for preliminary analysis of suspect samples, which can be used in triaging possible contaminated sites (e.g., sites contaminated or thought to be contaminated by biowarfare agents). In some embodiments, the methods involve testing for the presence of protein in the suspect sample; optionally, the sample can also be tested for the presence of sugar, and/or for pH determination. Specific embodiment methods are carried out in tubes or other reaction vessels, others are carried out in a pad format, and still others are carried out in a test strip format. Kits for carrying out the described methods are also provided.
    Type: Grant
    Filed: May 14, 2004
    Date of Patent: October 25, 2005
    Assignee: 20/20/GeneSystems, Inc.
    Inventors: Vladimir Knezevic, Dan-Paul Hartmann, Jonathan Cohen, Elizabeth Marcus
  • Patent number: 6770485
    Abstract: Provided herein are methods for preliminary analysis of suspect samples, which can be used in triaging possible contaminated sites (e.g., sites contaminated or thought to be contaminated by biowarfare agents). In some embodiments, the methods involve testing for the presence of protein in the suspect sample; optionally, the sample can also be tested for the presence of sugar, and/or for pH determination. Specific embodiment methods are carried out in tubes or other reaction vessels, others are carried out in a pad format, and still others are carried out in a test strip format. Kits for carrying out the described methods are also provided.
    Type: Grant
    Filed: February 21, 2003
    Date of Patent: August 3, 2004
    Assignee: 20/20 GeneSystems, Inc.
    Inventors: Vladimir Knezevic, Dan-Paul Hartmann, Jonathan Cohen, Elizabeth Marcus
  • Publication number: 20040081987
    Abstract: The present invention is directed to a device and a method for detecting biomolecules in a tissue section or other two-dimensional sample by creating “carbon copies” of the biomolecules eluted from the sample and visualizing the biomolecules on the copies using antibodies or DNA probes having specific affinity for the biomolecules of interest. Thin membranes in a stacked or layered configuration are applied to the sample, such as a tissue section, and reagents and reaction conditions are provided so that the biomolecules are eluted from the sample and transferred onto each of the stacked membranes thereby producing multiple replicas of the biomolecular content of the sample.
    Type: Application
    Filed: July 25, 2003
    Publication date: April 29, 2004
    Applicants: 20/20 GeneSystems, Inc., The Govt. of the USA as represented by the Secretary of the Dept. of Health and Human Sevs.
    Inventors: Vladimir Knezevic, Michael R. Emmert-Buck
  • Publication number: 20030180961
    Abstract: Provided herein are methods for preliminary analysis of suspect samples, which can be used in triaging possible contaminated sites (e.g., sites contaminated or thought to be contaminated by biowarfare agents). In some embodiments, the methods involve testing for the presence of protein in the suspect sample; optionally, the sample can also be tested for the presence of sugar, and/or for pH determination. Specific embodiment methods are carried out in tubes or other reaction vessels, others are carried out in a pad format, and still others are carried out in a test strip format. Kits for carrying out the described methods are also provided.
    Type: Application
    Filed: February 21, 2003
    Publication date: September 25, 2003
    Applicant: 20/20 GeneSystems, Inc.
    Inventors: Vladimir Knezevic, Dan-Paul Hartmann, Jonathan Cohen, Elizabeth Marcus
  • Patent number: 6602661
    Abstract: The present invention is directed to a device and a method for detecting biomolecules in a tissue section or other two-dimensional sample by creating “carbon copies” of the biomolecules eluted from the sample and visualizing the biomolecules on the copies using antibodies or DNA probes having specific affinity for the biomolecules of interest. Thin membranes in a stacked or layered configuration are applied to the sample, such as a tissue section, and reagents and reaction conditions are provided so that the biomolecules are eluted from the sample and transferred onto each of the stacked membranes thereby producing multiple replicas of the biomolecular content of the sample.
    Type: Grant
    Filed: November 20, 2000
    Date of Patent: August 5, 2003
    Assignees: 20/20 GeneSystems, Inc., The United States of America as represented by the Department of Health and Human Services
    Inventors: Vladimir Knezevic, Michael R. Emmert-Buck